

One commentor requested to add comprehensive biomarker coverage for biomarker testing for the New Mexico Medicaid beneficiaries in line with N.M. Stat. § 59A-23-7.18.

State response: State agrees and has added the following language to SPA:

1. Biomarker Coverage (BC). Biomarker tests are reimbursed on a fee schedule basis when medically necessary. Except as otherwise noted in the state plan. The agency's fee schedule rates were set as of January 5, 2024, and are effective for services provided on or after that date. **Medically necessary biomarker tests, which include ones with an NDC or LDC, ones that are recommended by the FDA for pharmacologic monitoring, or ones recommended in a national guideline, may be incorporated into the agency's fee schedule after January 5, 2024 and shall and be effective for biomarker tests provided either on or after January 5, 2024, or the date a Medicare rate was established for the biomarker test, whichever is later. All rates are published on the New Mexico Medicaid website.**